Why Immunotherapy Fails in Multiple Myeloma

被引:6
|
作者
Rodriguez-Lobato, Luis Gerardo [1 ,2 ]
Oliver-Caldes, Aina [1 ,2 ]
Moreno, David F. [1 ,2 ]
de Larrea, Carlos Fernandez [1 ,2 ]
Blade, Joan [1 ,2 ]
机构
[1] Hosp Clin Barcelona, Dept Hematol, Amyloidosis & Multiple Myeloma Unit, Barcelona 08036, Spain
[2] Inst Invest Biomed August Pi & Sunyer IDIBAPS, Barcelona 08036, Spain
来源
HEMATO | 2021年 / 2卷 / 01期
基金
欧盟地平线“2020”;
关键词
multiple myeloma; immunotherapy; daratumumab; BCMA; bi-specific T cell engagers; chimeric antigen receptor; relapse; cytokine-release syndrome; CHIMERIC-ANTIGEN-RECEPTOR; CAR-T-CELLS; IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT; FIBROBLAST ACTIVATION PROTEIN; MARROW STROMAL CELLS; B-CELL; ANTITUMOR-ACTIVITY; MATURATION ANTIGEN; OPEN-LABEL; CANCER-IMMUNOTHERAPY;
D O I
10.3390/hemato2010001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multiple myeloma remains an incurable disease despite great advances in its therapeutic landscape. Increasing evidence supports the belief that immune dysfunction plays an important role in the disease pathogenesis, progression, and drug resistance. Recent efforts have focused on harnessing the immune system to exert anti-myeloma effects with encouraging outcomes. First-in-class anti-CD38 monoclonal antibody, daratumumab, now forms part of standard treatment regimens in relapsed and refractory settings and is shifting to front-line treatments. However, a non-negligible number of patients will progress and be triple refractory from the first line of treatment. Antibody-drug conjugates, bispecific antibodies, and chimeric antigen receptors (CAR) are being developed in a heavily pretreated setting with outstanding results. Belantamab mafodotin-blmf has already received approval and other anti-B-cell maturation antigen (BCMA) therapies (CARs and bispecific antibodies are expected to be integrated in therapeutic options against myeloma soon. Nonetheless, immunotherapy faces different challenges in terms of efficacy and safety, and manufacturing and economic drawbacks associated with such a line of therapy pose additional obstacles to broadening its use. In this review, we described the most important clinical data on immunotherapeutic agents, delineated the limitations that lie in immunotherapy, and provided potential insights to overcome such issues.
引用
收藏
页码:1 / 42
页数:42
相关论文
共 50 条
  • [21] Immunotherapy for the treatment of multiple myeloma
    Boussi, Leora S.
    Avigan, Zachary M.
    Rosenblatt, Jacalyn
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [22] Immunotherapy for the treatment of multiple myeloma
    Jung, Sung-Hoon
    Lee, Hyun-Ju
    Vo, Manh-Cuong
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 111 : 87 - 93
  • [23] Cellular immunotherapy in multiple myeloma
    Manh-Cuong Vo
    Lakshini, Thangaraj Jaya
    Jung, Sung-Noon
    Choi, Duck
    Park, Hye-Seong
    Tan-Huy Chu
    Lee, Hyun-Ju
    Kim, Hyeoung-Joon
    Kim, Sang-Ki
    Lee, Je-Jung
    KOREAN JOURNAL OF INTERNAL MEDICINE, 2019, 34 (05): : 954 - 965
  • [24] Immunopathogenesis and immunotherapy of multiple myeloma
    Tamura, Hideto
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (03) : 278 - 285
  • [25] Active immunotherapy of multiple myeloma
    Houet, Leonora
    Veelken, Hendrik
    EUROPEAN JOURNAL OF CANCER, 2006, 42 (11) : 1653 - 1660
  • [26] Cellular Immunotherapy for Multiple Myeloma
    Rosenblatt, Jacalyn
    Avigan, David
    CANCER JOURNAL, 2019, 25 (01): : 38 - 44
  • [27] Immunodeficiency and immunotherapy in multiple myeloma
    Pratt, Guy
    Goodyear, Oliver
    Moss, Paul
    BRITISH JOURNAL OF HAEMATOLOGY, 2007, 138 (05) : 563 - 579
  • [28] IMMUNOTHERAPY IN MULTIPLE MYELOMA: EXPERIENCE OF THE MULTIPLE MYELOMA GIMEMA LAZIO GROUP
    Vozella, F.
    Siniscalchi, A.
    Rizzo, M.
    Za, T.
    Antolino, G.
    Coppetelli, U.
    Piciocchi, A.
    Andriani, A.
    Annibali, O.
    De Rosa, L.
    Cimino, G.
    La Verde, G.
    De Stefano, V.
    Cantonetti, M.
    di Toritto, T. Caravita
    Foa, R.
    Petrucci, M. T.
    HAEMATOLOGICA, 2019, 104 : 117 - 117
  • [29] Immunotherapy in Multiple Myeloma: Experience of the Multiple Myeloma Gimema Lazio Group
    Vozella, Federico
    Siniscalchi, Agostina
    Rizzo, Manuela
    Za, Tommaso
    Antolino, Giusy
    Coppetelli, Ugo
    Piciocchi, Alfonso
    Andriani, Alessandro
    Annibali, Ombretta
    De Rosa, Luca
    Cimino, Giuseppe
    La Verde, Giacinto
    De Stefano, Valerio
    Cantonetti, Maria
    di Toritto, Tommaso Caravita
    Foa, Robin
    Petrucci, Maria Teresa
    BLOOD, 2018, 132
  • [30] Why is amyloidosis not multiple myeloma?
    Corre, Jill
    BLOOD, 2021, 138 (17) : 1514 - 1515